Opko Health (OPK) Acquires Two New Phase 3 Products
Opko Health (NYSE: OPK) entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV) Announces Extension of Exchange Offer for Pharmacyclics (PCYC)
- Crown Castle (CCI) to Acquire Sunesys in $1B Deal (PWR)
- BioLineRx (BLRX) Announces Completion of BL-8040 Phase 2 Dose-Escalation Stage
Create E-mail Alert Related CategoriesFDA, Mergers and Acquisitions
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!